Biotech ETFs Pop as Bristol-Myers Squibb Set to Acquire Celgene

Biotechnology sector-related exchange traded funds strengthened Thursday after Bristol-Myers Squibb (NYSE: BMY) agreed to acquire rival Celgene (NasdaqGS: CELG) in a $74 billion deal, reigniting hopes of further deals in the industry. The iShares Nasdaq Biotechnology ETF (NASDAQGM: IBB), which...